DIOSYNTH BIOTECHNOLOGY ANNOUNCES AGREEMENT WITH IMMUNOGEN, INC.

October 6, 2005

Applied Clinical Trials

Diosynth Biotechnology to Manufacture Antibody for ImmunoGen

Research Triangle Park, North Carolina – October 6, 2005 – Diosynth Biotechnology, Inc. is pleased to announce the execution of an agreement with ImmunoGen, Inc. (Cambridge, MA) for the production of antibody to be used in the manufacture of ImmunoGen's huN901-DM1 anticancer compound.

Under this agreement, Diosynth Biotechnology will undertake technology transfer and conduct process and analytical development work related to production of ImmunoGen's huN901 antibody. Diosynth will then manufacture - under cGMP - bulk huN901 antibody for ImmunoGen utilizing the Diosynth cell-culture, fed-batch technology. ImmunoGen intends to use this antibody in the manufacture of future huN901-DM1 clinical materials.

"We are pleased to have been selected by ImmunoGen to produce antibody for their most-advanced product candidate," stated Richard A. Basile, VP of Diosynth Sales and Marketing Group. "ImmunoGen's choice of Diosynth further underscores the reputation of Diosynth Biotechnology as a leader in process development and the manufacture of cGMP-grade monoclonal antibody, consistent with our strength in the global biotherapeutics CMO arena."

Diosynth Biotechnology

Diosynth Biotechnology supplies contract manufacturing services for the global biotechnology industry. The company has an 80-year heritage in biologics manufacturing and is a global leader in technology-driven process development and cGMP manufacturing of recombinant proteins, monoclonal antibodies and peptides. We help our customers succeed by developing scalable and robust processes and by driving products efficiently, rapidly and cost-effectively from preclinical development to market supply. Diosynth Biotechnology serves pharmaceutical and biopharmaceutical customers globally and operates FDA-, Health Canada- and EMEA-inspected cGMP manufacturing facilities in Research Triangle Park, NC USA, and Oss, the Netherlands. Diosynth Biotechnology is a division of Akzo Nobel's human healthcare business unit Organon.

The Akzo Nobel Safe Harbor Statement (below) applies to this press release. For more information: www.diosynthbiotechnology.com

Related Content:

News